Sidley has advised Sino Biopharmaceutical Limited (through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) on the deal. Sino Biopharmaceutical Limited, through its subsidiary Chia...
Sino Biopharmaceutical and AstraZeneca Sign Exclusive Licensing Agreement for TQC3721
Simcere and Boehringer Ingelheim Enter €1.05 Billion Licensing and Collaboration Agreement for Preclinical IBD Treatment
Sidley has advised Simcere Pharmaceutical Group Ltd. on the deal. Simcere Pharmaceutical Group Ltd. has entered into a licensing and collaboration agreement with Boehringer Ingelheim valued...
Carlyle’s Sale of its Entire Stake in McDonald’s China Business
JunHe advised Carlyle on the deal. The Carlyle Group announced that McDonald’s Corporation had agreed to acquire all of the 28% equity interest held by Carlyle...
Resolian’s Acquisition of Denali Medpharma
Sidley Austin represented Resolian in the transaction. Resolian, a global bioanalytical contract research organization (CRO), announced the acquisition of Denali Medpharma (Denali), a leading China-based bioanalytical CRO....
Guardant Health’s Partnership with Adicon
Sidley represented Guardant Health on the deal. Guardant Health, Inc (Nasdaq: GH) announced its strategic partnership with Adicon to offer comprehensive genomic profiling tests to accelerate...
Ferring Pharmaceuticals’ Collaboration with Hybio Pharmaceutical Co.
Sidley Austin advised Ferring Pharmaceuticals on the deal. Ferring Pharmaceuticals (China) Co., Ltd. announced its strategic collaboration with Hybio Pharmaceutical Co., Ltd. where the Marketing Authorization of Cetrotide...
AstraZeneca’s Strategic Collaboration With Junshi Biosciences
Sidley Austin LLP advised AstraZeneca China on the deal. AstraZeneca China announced a strategic collaboration with Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences). AstraZeneca China will be...